An observational study in Aortic Aneurysm, Endovascular Aortic Repair and Stent-Graft Endoleak, sponsored by University Hospital Muenster. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-03.
Sponsored by University Hospital Muenster · Observational
The goal of this registry is to evaluate the semibranch in branched endovascular arotic repair, which is a new tool in endovascular branched aortic repair.
The main question it aims to answer are:
Patients with pararenal or thoracoabdominal aortic pathology, who are treated with a endovascular semibranch stentgraft
bEVAR with a custom made abdominal aortic multibranch, which incorporates the semibranch design
Freedom from target vessel instability
Primary patency and freedom from stenosis of the semibranch
Time frame: 30 days after intervention
Mortality
Overall mortality rate during 30 days after intervention
Time frame: 30 days after intervention
Technical success
cannulation and stentgrafting ot the semibranches
Time frame: 12 hours after intervention
Morbidity
Access site, bowel ischemia, kidney failure, paraplegia
Time frame: During follow up period (up to 3 years)
Freedom of Endoleak type I and III
Abscence of endoleaks arising from the semibranch
Time frame: During follow up period (up to 3 years)
Long term mortality
Overall mortality up to 3 years
Time frame: During follow up period (up to 3 years)
Branch patency
Primary patency of all branches
Time frame: During follow up period (up to 3 years)
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital Muenster